Clinical trials: Prostate Disease
Benign Prostatic Hyperplasia (BPH)
Study of Median Lobe Prostatic UroLift Procedure
The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02625545
- Testing
- UroLift System procedure
- Volunteers
- 45 people
- Sponsor
- NeoTract, Inc.
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
Gall Bladder Disease, Bile Duct Diseases
AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study
This clinical registry study aims to evaluate the safety and effectiveness of the AE05ML device for ligating vessels and tissue structures during laparoscopic surgery using Hem-o-lok® Medium Large (ML) polymer clips.
- Conditions
- Gall Bladder Disease, Bile Duct Diseases, Acute Cholecystitis, Kidney
- Trial name
- AE05ML (NCT06364865)
- Testing
- laparoscopic procedure
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Teleflex
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Metastatic Hormone-Sensitive Prostate Cancer
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making.
- Trial name
- NCT06452212
- Testing
- No Intervention
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Korea, Inc.
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Prostate Cancer
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
The purpose of this study is to learn if the study drug, [225Ac]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.
- Trial name
- SatisfACtion (NCT05983198)
- Testing
- 225Ac-PSMA-R2, 68Ga-PSMA-R2, 68Ga-PSMA-11
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.
- Trial name
- NCT00285675
- Testing
- DN-101 (calcitriol) - Drug
- Where
- 13 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Novacea
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Male Infertility, Benign Prostatic Hyperplasia
The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
Spermotrend is a natural based product manufactured by Catalysis Laboratories. Its composition contains different essential elements for spermatogenesis: selenium, zinc and fructose.
- Conditions
- Male Infertility, Benign Prostatic Hyperplasia, Spermatogenesis and Semen Disorders
- Trial name
- NCT05222841
- Testing
- Spermotrend
- Where
- Nicaragua
- Volunteers
- 150 people
- Sponsor
- Catalysis SL
Prostate Cancer
PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study
The main hypothesis of this study is to demonstrate that the use of the ConfirmMDx for Prostate Cancer test in previously biopsied patients improves urologists' patient management by reducing unnecessary repeat biopsies…
- Trial name
- PASCUAL (NCT02250313)
- Where
- 15 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- MDx Health
Prostate Cancer
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones.
- Trial name
- NCT00005073
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Hyperplasia
Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
Adherence and length of therapy with 5-alpha reductase inhibitor (5ARI) treatment may be associated with improved clinical outcomes of enlarged prostate (EP) as well as lower health care costs.
- Trial name
- NCT01381510
- Testing
- 5-alpha Reductase Inhibitor (5ARI)
- Volunteers
- 54,459 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
BR55 in Prostate Cancer: an Exploratory Clinical Trial
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.
- Trial name
- NCT01253213
- Testing
- BR55
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Bracco Diagnostics, Inc
Prostate Cancer
CART-PSMA Cells for Advanced Prostate Cancer
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
- Trial name
- NCT05656573
- Testing
- CART-PSMA cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nova Therapeutics LLC
Prostate Cancer
MyProstateScore Equivalency With and Without DRE
The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.
- Trial name
- NCT05700370
- Testing
- MyProstateScore
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LynxDx
Benign Prostate Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia
- Trial name
- NCT02390882
- Testing
- HGP0412 capsule, HIP1402 capsule
- Where
- South Korea
- Volunteers
- 494 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.